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p38We have explored the possible role of dual speciﬁcity phosphatases (DUSPs) on acute EGF-mediated ERK sig-
nalling using high content imaging and a delayed MEK inhibition protocol to distinguish direct and indirect
effects of the phosphatases on ERK activity. Using siRNAs, we were unable to ﬁnd evidence that any of the
MAPK phosphatases (MKPs) expressed in HeLa cells acts directly to dephosphorylate ppERK1/2 (dual phos-
phorylated ERKs 1 and/or 2) in the acute time-frame tested (0–14 min). Nevertheless, siRNAs against two
p38/JNK MKPs (DUSPs 10 and 16) inhibited acute EGF-stimulated ERK activation. No such effect was seen
for acute effects of the protein kinase C activator PDBu (phorbol 12,13 dibutyrate) on ERK activity, although
effects of EGF and PDBu on ERK-dependent transcription (Egr-1 luciferase activity) were both reduced by
siRNA targeting DUSPs 10 and 16. Inhibition of EGF-stimulated ERK activity by these siRNAs was reversed
by pharmacological inhibition of p38 MAPK and single cell analysis revealed that the siRNAs did not inﬂuence
the nuclear-cytoplasmic distribution of ppERK1/2. Thus, DUSPs 10 and 16 are positive regulators of activa-
tion, apparently acting bymodulating cross-talk between the p38 and ERK pathways. A simpliﬁedmathematical
model of this scenario accurately predicted the experimental data, supporting the conclusion that the major
mechanism by which MKPs inﬂuence acute EGF-stimulated ERK responses is the negative regulation of p38,
resulting in the positive regulation of ERK phosphorylation and activity.
© 2012 Elsevier Inc. Open access under CC BY license.1. Introduction
The extracellular signal-regulated kinases (ERKs) 1 and 2 are mi-
togen-activated protein kinases (MAPKs) that are regulated by a di-
verse array of extracellular stimuli and play key roles in the control
of cell fate in health and disease. They are activated by MAPK/ERK ki-
nases (MEKs) 1 and 2 which catalyse the phosphorylation of Thr and
Tyr residues in the ERK TEY activation loops [1–4]. TEY phosphorylated
ERKs 1 and 2 (ppERK1/2) can phosphorylate a growing list of substrate
proteins in the nucleus and cytoplasm and thereby control a large num-
ber of cellular activities [2–4]. The speciﬁcity of biological outcome from
activation of ERKs is largely achieved through tight control of the dura-
tion,magnitude and localization of ERK signals. Activation of ERKs com-
monly causes their translocation from the cytoplasm to the nucleus,
which is necessary for the transcription of many immediate earlyUniversity of Bristol, 1 Whitson
+44 117 3313035.
Ardle).
 license.genes such as c-Fos, c-Jun and early growth response gene-1 (Egr-1)
[5–9]. In ﬁbroblasts and epithelial cells, sustained ERK activity causes
expression and stabilization of immediate early gene products, culmi-
nating in G1/S transition [7–10]. This does not occur in cells where nu-
clear localization of ERK is prevented [11]. In contrast, transient ERK
signals similarly cause the transcription of immediate early genes, but
this is not sustained, and the protein products are rapidly degraded
[7–11].
Epidermal growth factor (EGF) family ligands act via ErbB family
tyrosine kinase receptors [12–14]. They are activated when ligand
binding promotes receptor dimerization and consequent self phos-
phorylation on tyrosines. This facilitates recruitment of adapter pro-
teins or enzymes that initiate signalling to a number of effectors
including components of the ERK, JNK (c-Jun N-terminal kinase)
and p38 (stress response kinase) MAPK pathways [12–14]. In many
systems EGF causes a characteristically transient activation of ERK.
Given the importance of signal duration in determining cell fate,
and the importance of these receptors and effectors as therapeutic
targets, there is considerable interest in the molecular mechanisms
determining the kinetics of this response [2,7–9,12–18]. A large
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clude receptor internalization [12,20] as well as ERK-mediated nega-
tive feedback at the level of SOS or Raf-1 [19]. Such mechanisms
dictate the kinetics of the input for activation, and act in concert
with protein phosphatases to shape ERK signals. In this regard the
MAPK phosphatases (MKPs) are receiving increasing attention as
physiological regulators of ERK signalling and as potential therapeutic
targets. The MKP family of dual speciﬁcity phosphatases (DUSPs) can
dephosphorylate and anchor ERKs, thereby inﬂuencing all three
major determinants of ERK action (amplitude, kinetics and compart-
mentalization). The three groups of DUSPs that target MAPKs
[15,21–31] are i) the nuclear-inducible MKPs (DUSP 1/MKP-1, DUSP
2/PAC1, DUSP 4/MKP-2 and DUSP 5/VH3), which all dephosphorylate
ERK and, with the exception of DUSP 5, also dephosphorylate JNK
and/or p38, ii) the cytoplasmic ERK MKPs (DUSP 6/MKP-3, DUSP 7/
PYST2 and DUSP 9/MKP-4), which preferentially target ERK and iii)
the JNK/p38 MKPs (DUSP 8/VH5, DUSP 10/MKP-5 and DUSP 16/
MKP-7). Many stimuli cause an ERK-mediated increase in expression
of nuclear-inducible MKPs that can dephosphorylate and anchor ERKs
within the nucleus and thereby inﬂuence responses to sustained ERK
activating stimuli [15]. Much less is known about the roles of DUSPs
in shaping transient responses to stimuli such as EGF, where insensi-
tivity to cycloheximide implies dependence on pre-existing (rather
than induced) phosphatases [15,16]. However, we have recently
screened for effects of siRNA-mediated DUSP knock-down on acute
(5 min) EGF-stimulated ERK activation. We found that knock-down
of individual nuclear-inducible DUSPs had no effect whereas EGF-
stimulated ERK phosphorylation was reduced by siRNAs targeting
DUSPs 3, 9,10 and 16 [15]. The DUSP 16 knock-down data are consis-
tent with recent work showing that transfection with DUSP 16 can in-
crease and prolong EGF-stimulated ERK phosphorylation [32].
Although DUSP 16 is relatively inactive toward ppERKs as substrates,
it can bind and scaffold ERK2. Interestingly, it was shown to scaffold
and retain ppERK1/2 in the cytoplasm of COS-7 cells, so that it actual-
ly inhibited effects of a protein kinase C (PKC) activator on expression
of ERK target genes, as measured using AP-1- and SRE-luciferase re-
porters [32]. This illustrates the potential for DUSPs to act as positive
or negative regulators of ERK, with their overall effects reﬂecting their
ability to scaffold ERKs and to inﬂuence upstream feedback and cross-
talk, as well by directly dephosphorylating their preferred MAPK
targets.
Here, we have explored the possible role of DUSPs in shaping acute
ERK responses to EGF inHeLa cells, using a high content imaging system
for quantiﬁcation of effects on ERK activation and nuclear-cytoplasmic
distribution [15,16,33,34], and a “delayed MEK inhibition” protocol in
which ERKdephosphorylation is followed after addition of aMEK inhib-
itor. This protocol is intended to reveal ERK inactivation kinetics in iso-
lation (i.e. without any inﬂuence of negative feedback upstream of ERK
or positive feed-forward activation fromMEK) in order to delineate di-
rect and indirect effects of siRNA-mediated DUSP knock-downs. We
validated this approach by monitoring and modeling activation of
ERK2 as compared to K52R-ERK2 (a catalytically inactive mutant used
to prevent ERK-mediated negative feedback) and D319N-ERK2 (a mu-
tant deﬁcient in D-domain-dependent binding to proteins including
DUSPs). We then used this approach to test for effects of siRNA-
mediated DUSP knock-down and found no evidence for direct dephos-
phorylation of ERKs by DUSPs after acute activationwith EGF. However,
siRNAs targeting DUSPs 10 and 16 reduced the amplitude and duration
of EGF-stimulated ERK phosphorylation responses, effects thatwere not
attributable to scaffolding ERK in the cytoplasm. Instead, the effects of
these siRNAs were prevented by p38 inhibition, implying that these
DUSPs oppose upstream p38-mediated negative regulation of ERK.
Thus, in this model the major DUSPs shaping acute EGF-mediated ERK
responses are in fact JNK/p38 speciﬁc MKPs, acting by modulating
cross-talk between MAPK cascades, rather than by direct effects on
ERK dephosphorylation or scaffolding.2. Materials and methods
2.1. Cell culture, transfection and transduction
HeLa cells (from the European Cell and Culture Collection, Porton
Down, UK) were cultured in 10% FCS-supplemented Dulbecco's modi-
ﬁed Eagle's medium (DMEM) without sodium pyruvate (Invitrogen
Paisley, UK). For 96-well plate experiments, they were harvested by
trypsinization and seeded at 3–5×103cells/well in Costar plain black-
wall 96-well plates (Corning, Arlington, UK). They were maintained in
culture for 2 days and then transferred to medium containing 0.1%
FCS for 16–24 h before stimulation for various periods with EGF
(Sigma-Aldrich, Gillingham, UK) or PDBu (phorbol 12, 13-dibutyrate,
Sigma-Aldrich). The stimulations were terminated by washing the
cells in 150 μl/well cold (b4 °C) phosphate-buffered saline (PBS) and
placing the plates on ice. The PBS was removed and the cells were
ﬁxed by adding 50 μl/well of 4% paraformaldehyde (PFA) in PBS and in-
cubating on a rocking platform for 5 min at room temperature. The PFA
solution was then removed and the cells were permeabilized by adding
50 μl/well of –20 °C methanol and incubating for 5 min at –20 °C. For
some experiments, cells were treated with a 10 μM PD184352 (Enzo
Life Sciences, Exeter, UK) to inhibit MEK, 10 μM SP600125 (Sigma-
Aldrich) to inhibit JNK, or with 10 μM SB203580 (Sigma-Aldrich) to in-
hibit p38 MAPK (timing details for inhibitor addition are given in the
ﬁgure legends).
For some experiments siRNA duplexes were used to knock-down
endogenous ERK1 and 2, and recombinant adenovirus (Ad) were
used to add-back either wild-type or mutant ERK2-green ﬂuorescent
protein (GFP) reporters. Brieﬂy, cells were transfected using RNAi-
MAX reagent (Invitrogen) and the manufacturer's reverse transfec-
tion protocol was used with 2 siRNA duplexes (Qiagen, Crawley,
UK) each for ERK1 and ERK2 as described [15,16,33,34]. A mixture
of all 4 ERK1/2 duplexes or control siRNA against GFP (Ambion, War-
rington, UK) was used in experiments at 2.5 nM total concentration.
The cells were cultured for 16 h after siRNA transfection and then
transduced with 1.5×106plaque-forming units (pfu)/ml of Ad
expressing wild-type ERK2-GFP, K52R ERK2-GFP or D319N ERK2-
GFP vector in DMEM with 2% FCS. These Ad were created using viral
shuttle vectors constructed by subcloning a KpnI–NotI digest of
ERK2-GFP in pEGFP-N1 (a gift from Prof. Louis Luttrell, Medical Uni-
versity of South Carolina, Charleston, USA) into a corresponding di-
gest of pacAd5CMV K-N pA (donated by Prof. Beverly Davidson,
University of Iowa, Iowa City, USA). K52R, and D319N mutations
were introduced using a QuikChange PCR-based mutagenesis kit
(Stratagene, Amsterdam, NL) as described [15,16,33,34]. The Ad-
containing medium was removed after 4–6 h and replaced with
fresh DMEM supplemented with 0.1% FCS. The cells were then main-
tained for 16–24 h in this medium before stimulation. For some ex-
periments siRNA duplexes were used to knock-down expression of
endogenous DUSPs. To do so cells were transfected (as above) with
10 nM SMARTpool siRNA mixtures (Dharmacon, Cramlington, UK)
targeting individual DUSPs (alone or in combination) or with a con-
trol non-targeting siRNA mixture, as described [15,16,33,34]. The
cells were maintained in DMEM with 10% FCS for 24 h after siRNA
transfection and then transferred to medium with 0.1% FCS for
16–14 h before stimulation, as above.
2.2. Immunohistochemistry and imaging
Cells were cultured in 96 well plates and after appropriate trans-
duction and transfection, were stimulated and then ﬁxed and per-
meabilized as described above. To stain endogenous ERKs, cells
were blocked with 5% normal goat serum in PBS and then probed
with mouse anti-ppERK1/2 monoclonal antibody (clone MAPK-YT,
1:200, Sigma-Aldrich) and rabbit anti-ERK1/2 monoclonal (clone
137F5, 1:100, Cell Signaling Technology, Danvers, MA, USA) in PBS.
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goat anti-rabbit secondary antibodies (1:200, Invitrogen) and DAPI/
PBS (600 nM) were used to visualize ppERK1/2 and ERK1/2, and to
stain nuclei (respectively) as described [15,16,33,34]. For imaging
ppERK2 in cells expressing ERK2-GFP, cells were counterstained
with mouse anti-ppERK1/2 monoclonal (1:200) and Alexa 546-
conjugated goat anti-mouse secondary (1:200) as above. Image ac-
quisition in each well was performed on an IN Cell Analyzer 1000
(GE Healthcare, Amersham, UK) high content imaging platform,
using a 10× objective and 360 nm (DAPI), 475 nm (Alexa 488 and
GFP) and 535 nm (Alexa 546) excitation ﬁlters, with 460 nm,
535 nm and 620 nm emission ﬁlters, respectively, and with a 61002
trichroic mirror (GE Healthcare). Analysis of endogenous ERK1/2
and ppERK1/2 was performed using the Multi-target Analysis algo-
rithm in the IN Cell Analyzer Workstation (GE Healthcare) using
DAPI images to deﬁne nuclear perimeters and ERK1/2 or ERK2-GFP
staining to deﬁne cell perimeters. These were then used as masks
for quantiﬁcation whole cell ppERK1/2 staining or nuclear and cyto-
plasmic ERK2-GFP staining. Imaging data are reported as ppERK1/2
intensity (mean ﬂuorescence intensity per cell) or as a ratio of nuclear
to cytoplasmic ERK2-GFP stain intensity (N:C ratio). For most experi-
ments population averaged measures are reported, but for some ex-
periments frequency–distribution curves were generated from
measures in individual cells, or N:C ERK1/2 ratios were calculated
for cells sorted into sub-populations according to the whole cell
ppERK1/2 stain intensity as described [15,16,33,34].
2.3. Quantitative PCR
DUSP knock-down efﬁciency was tested as described [33,34] in
HeLa cells that were simultaneously plated and transfected in 24-
well plates (3.125×104cells/well) with 50 nM non-targeting control
or SMARTpool siRNA mixtures targeting human DUSP 2, DUSP 10 orFig. 1. Time course of ERK activation and inactivation. Upper panels: HeLa cells were seeded
1 μMPDBu, 10 nM EGF or medium alone (open circles). After 0 or 5–120 min they were ﬁxed
acquisition and analysis (as described in Materials and methods). Average whole cell ppER
internal control values (the highest observed ppERK1/2 levels, which were 385±22 (n=
The data shown are means±SEMs (n=3) pooled from 3 separate experiments each with
with EGF or PDBu (ﬁlled circles) or medium alone (open triangles), and then ﬁxed and sta
was used and ppERK1/2 levels were measured at 2 min intervals. For some cells, the MEK in
bar) in order to follow ERK inactivation after MEK inhibition. Whole cell ppERK1/2 measure
and the data shown are means±SEMs (n=3–7) pooled from 7 separate experiments each
were estimated for the entire series of experiments (assuming exponential decay after
±0.14 min (n=16) in the presence of PDBu and EGF, respectively.DUSP 16 (Dharmacon). Twenty-four hours after plating, cells were
serum starved overnight and extraction of total RNA was performed
24 h later using an RNeasy kit according to the manufacturer's in-
structions (Qiagen). Contaminating genomic DNA was removed
from columns using an additional DNase (Qiagen) digestion step.
Complementary DNA was then prepared for 1 μg of each total RNA
sample using a cloned avian myeloblastosis virus ﬁrst-strand synthe-
sis kit according to the manufacturer's instructions (Invitrogen).
cDNAs were then quantiﬁed relative to expression of human
GTPase-activating protein using the following primers: human
GTPase-activating protein, 5′-GGG AAG GTG AAG GTC GGA GT-3′
and 5′-GAG TTA AAA GCA GCC CTG GTG A-3′; DUSP 2, 5′-AAA ACC
AGC CGC TCC GAC-3′ and 5′-CCA GGA ACA GGT AGG GCA AG-3′;
DUSP 10, 5′-GCC AGC CAC TGA CAG CAA C-3′ and 5′-TCC CAC ACT
GGT GAG CTT CC-3′; and DUSP 16, 5′-TCA CTG TAC TTC TGG GTA
AAC TGG AG-3′ and 5′-AAG GCT GAG AAA TGC AGG TAG G-3′. PCR
primers were mixed with 50 ng of reverse transcription-PCR template
and SYBR green PCR master mix (Applied Biosystems, Warrington,
UK), and the comparative CT method was used to detect relative ex-
pression curves on an ABI PRISM 7500 detection system (Applied
Biosystems).2.4. Luciferase assays
Luciferase assays were performed as described [33,34] in cells that
were transfected with siRNA, transduced with Ad vectors and plated
on Costar plain black-wall 96-well plates (Corning), but including
Ad Egr-1 Luciferase and Ad CMV β-galactosidase reporter vectors. Fol-
lowing treatment with PDBu or EGF, cells were washed in ice-cold
PBS, lysed and assessed for luciferase activity by chemical luminescence
following the addition of luciferin substrate (Promega, Southampton,
UK). β-galactosidase activity was used to correct luciferase activity forin 96-well imaging plates and kept in reduced (0.1%) serum for 16 h prior to addition of
and stained for endogenous ppERK1/2 and nuclei were stained with DAPI before image
K1/2 measures (arbitrary ﬂuorescence units, AFU) were calculated and normalized to
3) AFU and 448±20 (n=3) AFU for PDBu- and EGF-stimulated cells, respectively).
triplicate or quadruplicate wells. Lower panels: HeLa cells were cultured, stimulated
ined before image acquisition and analysis as above, except that a 14 min time course
hibitor PD184352 (10 μM) was added 6 min after the stimulus (open circles, horizontal
s were normalized to internal control values (6 min ppERK1/2 levels for each stimulus)
with triplicate or quadruplicate wells. Rates of ERK inactivation after MEK inhibition
MEK addition) and this revealed half times of 0.92±0.08 min (n=23) and 1.90
1005A.R. Finch et al. / Cellular Signalling 24 (2012) 1002–1011transfection efﬁciency, asmeasured following the addition of chlorophe-
nol red-β-D-galactopyranoside substrate (Roche, Hertfordshire, UK).
2.5. Statistical analysis and data presentation
The cell imaging experiments and luciferase reporter experiments
were performed at least 3 times, with 2–4 replicate wells for each
treatment in each experiment. In order to pool data from repeat ex-
periments, they were normalized according to internal control values
as described in the ﬁgure legends. Statistical analysis was by one- or
two-way ANOVA followed where appropriate by Bonferroni's post-
test, accepting Pb0.05 as statistically signiﬁcant. For some experi-
ments the half-time for reduction of ppERK1/2 or ppERK2 levels
was calculated by curve ﬁtting assuming one-phase exponential
decay. Statistical analysis and curve ﬁtting were performed using
GraphPad Prism version 5.01 (Graphpad Software Inc., La Jolla, CA,
USA).
2.6. Mathematical modelling
We developed a minimal mathematical model of the ERK pathway
based on previous models by introducing the positive- and negative-Fig. 2. Time course of EGF-stimulated ERK activation using a knock-down and add-back mo
siRNAs targeting ERK1/2 and were transduced with Ad expressing wild-type ERK2-GFP, or w
They were then kept in medium with 0.1% FCS for 16 h prior to stimulation (with 10 nM EG
course in cells stimulated without MEK inhibitor, whereas the right panels show time cours
ppERK2 measures were normalized to internal control values (6 min ppERK levels in cells w
6 separate experiments each with duplicate or triplicate wells. Rates of ERK inactivation afte
this revealed a half-time of 1.62±0.12 min (n=6) in cells expressing ERK2-GFP, that was si
by the Y261A or K52R mutations (1.40±0.02 min (n=3) and 1.72±0.17 min (n=5), respfeedback mechanisms present in the system [9,35–37]. In this model
we assume that each protein kinase (i.e. Ras, Raf, MEK, ERK, p38) has
only two possible states: active and inactive, and that the total
amount is conserved. The negative feedback mechanisms were as-
sumed to be allosteric inhibition, where ppERK and p38 are considered
as kinases [35]. The model equations are given in Supplemental Fig. 1.
3. Results and discussion
In the ﬁrst experiments we compared the time courses of ERK ac-
tivation using ﬂuorescence immunohistochemistry and automated
imaging to deﬁne whole cell levels of ppERK1/2 in HeLa cells stimu-
lated for up to 2 h with maximally effective concentrations of EGF
or PDBu (Fig. 1). These stimuli caused the expected increases in
ppERK1/2 levels [15,16,33,34]. Maximal responses were comparable,
at 385±22 (3) and 448±20 (3) arbitrary ﬂuorescence units (AFU)
for PDBu and EGF, respectively. As expected, the response to EGF
was rapid and transient (maximal at 5–10 min, reducing to less
than 50% maximal within 30 min), as compared to the slower and
more sustained effect of PDBu (maximal at 10–20 min, remaining at
least 50% maximal for 60 min). We also performed shorter time-
course experiments stimulating the cells for up to 14 min with EGFdel with wild-type and mutant ERK2-GFP reporters. HeLa cells were transfected with
ith Ad expressing D319N ERK2-GFP, Y261A ERK2-GFP or K52R ERK2-GFP, as indicated.
F for 0 or 2–14 min), ﬁxation, staining and imaging as above. The left panels show time
es with PD184352 (10 μM) added 6 min after the stimulus (horizontal bar). Whole cell
ith wild-type ERK2-GFP) and the data shown are means±SEMs (n=3–6) pooled from
r MEK inhibition were estimated (assuming exponential decay after MEK addition) and
gniﬁcantly increased by the D319N mutation (3.25±0.33 min (n=4), Pb0.05) but not
ectively).
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(maximal EGF and PDBu effects at 4–6 min or 8–14 min, respective-
ly). When the MEK inhibitor PD184352 was added 6 min after EGF
or PDBu, it caused a rapid inactivation of ERK with ppERK1/2 return-
ing to near basal levels within 4–8 min. Curve ﬁtting (assuming an
exponential reduction in the presence of the MEK inhibitor and ana-
lysing data from the entire series of experiments) revealed that the
PD184352-induced reversal of the PDBu effect was faster than re-
versal of the EGF effect (half-times 0.92±0.08 min (n=23) and
1.90±0.14 min (n=16), in PDBu- and EGF-stimulated cells,
respectively).
The effect of the MEK inhibitor demonstrates the importance of
continuous MEK activity for the observed ppERK1/2 responses and
provides a method for monitoring the kinetics of ERK inactivation in
isolation. That is, in normal cells ppERK1/2 responses are shaped by
feed-forward activation of MEK and by negative feedback and cross-
talk from other MAPK pathways upstream of MEK, as well as by direct
dephosphorylation of ERK1/2, but if MEK could be completely and in-
stantly inhibited (MEK inhibition after stimulation) ERK1/2 inactiva-
tion kinetics would reﬂect solely the direct dephosphorylation of
ppERK1/2. A similar approach was recently used by Aoki et al. to de-
ﬁne rate constants for ppERK1/2 dephosphorylation and this was val-
idated by demonstrating sensitivity to serine/threonine phosphatase
activity with calyculin A [38]. As an alternative approach, we used a
knock-down/add-back model in which inhibitory RNAs are used toFig. 3. Inﬂuence of DUSP knock-down on the time course of EGF-stimulated ERK activation. H
siRNAs targeting the nuclear-inducible DUSPs 1, 2, 4 and 5 (NI DUSP KD, upper panels), the
JNK/p38 DUSPs 10 and 16 (JNK/p38 DUSP KD, lower panels) and then kept in medium wit
staining and imaging as above. The left panels show time course in cells stimulated withou
added 6 min after the stimulus (horizontal bar). Whole cell ppERK1/2 measures were norm
and the data shown are means±SEMs (n=3) pooled from 3 separate experiments each w
siRNAs. Rates of ERK inactivation after MEK inhibition were estimated (assuming exponen
control siRNA and this was not signiﬁcantly different (P>0.05) to the half times in cells wknock-down endogenous ERK1/2 and recombinant Ad are used to
add-back wild-type or mutated ERK2-GFP reporters. We have previ-
ously characterized this model showing (by Western blotting, imag-
ing and functional readouts) that expression of endogenous ERK1/2
is reduced by over 90% and that the ERK2-GFP reporters are
expressed at levels comparable to control levels for endogenous
ERK1/2 [15,16,33,34]. As in previous experiments, we found that the
time courses for activation of ERK2-GFP by EGF and PDBu were com-
parable to those for activation of endogenous ERK1/2 (Figs. 1 and 2).
The speciﬁcity of ERK binding to partner proteins is regulated through
binding motifs including D (docking)- and DEF (docking site for ERK,
FXFP)-domains. These motifs can inﬂuence interaction of ERKs with
phosphatases [11,16,21,26–28] and such interactions can be per-
turbed by introducing speciﬁc mutations into ERK. The D319N muta-
tion of ERK prevents association with D-domain binding partners
whereas the Y261A mutation prevents DEF domain-dependent bind-
ing, and neither mutation alters the intrinsic catalytic activity of ERKs
[9,39]. In contrast, the K52R mutation prevents catalytic activity.
Using the knock-down/add-back protocol we obtained comparable
expression levels for wild-type ERK2-GFP, D319N ERK2-GFP, Y261A
ERK2-GFP and K52R ERK2-GFP (as judged by whole cell GFP mea-
sures, data not shown). The K52R mutation increased basal whole
cell ppERK1/2 levels (time 0 values were 140±6 (n=5) and
206 ±17 (n=5) AFU in cells expressing ERK2-GFP and K52R ERK2-
GFP, respectively) whereas no such effect was seen with the othereLa cells were transfected with control siRNA (Ctrl., all panels) or with a combination of
cytoplasmic ERK-directed DUSPs 6, 7 and 9 (Cyt. ERK DUSP KD, middle panels) or the
h 0.1% FCS for 16 h prior to stimulation (with 10 nM EGF for 0 or 2–14 min), ﬁxation,
t MEK inhibitor, whereas the right panels show time courses with PD184352 (10 μM)
alized to internal control values (6 min ppERK1/2 levels in cells with control siRNA)
ith duplicate or triplicate wells. *Pb0.05, **Pb0.01 for comparison of control and test
tial decay after MEK addition). The half-time was 2.61±0.30 min (n=3) in cells with
ith siRNAs targeting any of the DUSP families.
Fig. 4. Inﬂuence of JNK/p38 DUSP knock-down on the time course of EGF-stimulated
ERK activation. HeLa cells were transfected with control siRNA (Ctrl, all panels) or
with siRNAs targeting either DUSP 10 or DUSP 16. They were then kept in medium
with 0.1% FCS for 16 h prior to stimulation (with 10 nM EGF or 1 μM PDBu for 0 or
2–14 min), ﬁxation, staining and imaging as above. Whole cell ppERK1/2 measures
were normalized to internal control values (6 min ppERK1/2 levels in cells with control
siRNA) and the data shown are means±SEMs (n=3) pooled from 3 separate experi-
ments each with duplicate or triplicate wells. *Pb0.05, **Pb0.01 for comparison of con-
trol and test siRNAs.
1007A.R. Finch et al. / Cellular Signalling 24 (2012) 1002–1011mutants (Fig. 2 and Supplemental Fig. 2). EGF and PDBu caused
marked increases in ppERK2 levels with all 4 reporters and responses
to both stimuli were increased by the D319N mutation, but not by ei-
ther of the other mutations (Fig. 2 and Supplemental Fig. 2). When
the MEK inhibitor PD184352 was added after 6 min it caused a
rapid decline in ppERK2 levels under all conditions. Importantly how-
ever, the half-time for the reduction in ppERK1/2 was unaltered by
the K52R and Y261A mutations (P>0.05), but was increased at
least 2 fold by the D319N mutation in EGF-stimulated cells (half-time
increased from 1.62±0.12 min (6) to 3.25±0.33 min (4), Pb0.01)
and in PDBu-stimulated cells (half-time increased from
1.19 ±0.22 min (6) to 3.32±0.21 min (4), Pb0.01) (Fig. 2 and Supple-
mental Fig. 2). The simplest explanation for this increased half-time is
that ERK2 is dephosphorylated byD-domain containing phosphatase(s)
and it is well established that MKPs have N-terminal D-domains, which
determine substrate speciﬁcity [8,22]. By the same logic, the Y261Amu-
tation provides a negative control expected not to alter direct dephos-
phorylation of ERK2 by DUSP 1 and DUSP 4. The K52R mutation also
provides a control as it is thought to increase basal ppERK2 levels by
preventing ERK-dependent negative feedback and the lack of effect of
this mutation on half-time for ERK inactivation (in the presence of the
MEK inhibitor) is entirely consistent with this interpretation. To further
explore these possibilities we developed a mathematical model (Sup-
plemental Fig. 1), using previously described pathway architecture
and rate constants [19] to describe the effects of EGF on the ERK signal-
ling cascade in terms of a series of ordinary differential equations. We
used the data in Fig. 1 to train themodel parameters, simplifying ERK in-
activation to a single dephosphorylation step with a rate constant of
0.42 min−1. We then validated the model (model A=steps 1–4
shown in Supplemental Fig. 1) using the data from Fig. 2 and from Sup-
plemental data Fig. 2. Consistent with the interpretation above, the
model predictions closely paralleled the experimental datawhenwe as-
sumed a) that PD184352 causes complete and instantaneous blockade
of MEK, b) that the sole effect of the D319N mutation is to increase
the half-time for ERK inactivation from 1.62 to 3.25 min, and c) that
the sole effect of the K52R mutation is to prevent ERK-mediated nega-
tive feedback at the level of SOS or Raf (compare Figs. 2 and Supplemen-
tal Figs. 2 and 3).
Together, the mathematical and experimental approaches de-
scribed above demonstrate the potential for modulation of basal
and stimulated ppERK1/2 levels by direct alteration of dephosphory-
lation or by alteration of feedback, and the utility of delayed MEK in-
hibitor protocol for delineating these direct and indirect effects.
Accordingly, we next used these models to further explore possible
effects of DUSPs using siRNA to knock down endogenous DUSPs and
automated imaging to monitor activation of endogenous ERK1/2.
Combined knock-down of nuclear-inducible DUSPs 1, 2, 4 and 5 had
no measurable effect on ppERK1/2 responses to EGF or PDBu either
alone, or when PD184352 was added at 6 min (Fig. 3 and Supplemen-
tal Fig. 4). These data are not unexpected because induced expression
of these phosphatases would not occur in the short time-frame of
these experiments and because we have previously shown that indi-
vidual knock-downs of these DUSPs have no measurable effect on
acute (5 min) EGF-stimulated ppERK2 levels using our knock-down/
add-back protocol [15]. Combined knock-down of the cytoplasmic
ERK-directed DUSPs 6, 7 and 9 reduced ppERK1/2 responses to both
stimuli at all time points measured in the absence of PD184352 but,
importantly, did not alter the half-times for reduction in ppERK1/2
levels when PD184352 was added at 6 min (Fig. 3 and Supplemental
Fig. 4). Combined knock-down of the JNK/p38 DUSPs 10 and 16 re-
duced the EGF effect on ppERK1/2 at all time points measured and
made the response remarkably transient, returning to basal values
within 14 min (Fig. 3). This effect of DUSPs 10 and 16 knock-down
on response kinetics was conﬁrmed by two-way ANOVA in which
”time”, “knock-down” and the “time–knock-down interaction”
terms were all statistically signiﬁcant (Pb0.01). However, it was notassociated with any measurable change in the half-time for ppERK1/
2 inactivation in the delayed MEK inhibition protocol. Moreover, in
contrast to the situation with siRNAs targeting the cytoplasmic ERK
MKPs, knock-down of JNK/p38 MKPs speciﬁcally reduced responses
to EGF without any effect on the PDBu responses (compare Fig. 3
with Supplemental Fig. 4). We also conﬁrmed effectiveness of the
knock-down, as combined siRNAs targeting DUSPs 10 and 16 reduced
transcription of these targets (each by 80-90% as judged by qPCR)
without reducing DUSP 2 expression (not shown).
Exploring effects on ERK response kinetics further, we used siRNA
to knock-down DUSP 10 or 16 individually. Again, qPCR revealed tar-
get knock-down efﬁciency of 80–90% (not shown) and we found that
both manipulations inhibited EGF-stimulated ppERK1/2 responses at
all time points measured (Fig. 4). The effect of the DUSP 10 siRNA
was more pronounced than that of the DUSP 16 siRNA and neither
had any measurable effect on responses to PDBu (Fig. 4). We also
used pharmacological inhibition to test for dependence of these in-
hibitory effects on p38 or JNK. As shown (Fig. 5), siRNAs targeting
DUSPs 10 and 16 signiﬁcantly reduced ppERK1/2 responses elicited
by 10 min stimulation with EGF and this inhibitory effect was partial-
ly prevented by p38 inhibition (with SB203580) but not by JNK inhi-
bition (with SP600125). In parallel experiments PDBu-stimulated
ppERK1/2 responses were uninﬂuenced by the siRNAs (Fig. 5). More-
over, although there was an overall tendency for each of the inhibi-
tors to reduce ppERK1/2 levels alone, neither of them signiﬁcantly
inﬂuenced the PDBu-stimulated ppERK1/2 levels in the presence of
the control or test siRNAs (Fig. 5).
The data above suggest that the JNK/p38 MKPs have no direct ef-
fect on ERK activity in cells acutely stimulated with EGF (because
they have no effect on inactivation kinetics in the presence of the
MEK inhibitor) but instead have an indirect positive regulatory effect
that is overcome by siRNA-mediated knock-down. In these cells, PKC
is thought to feed into the ERK pathway by activation of Raf, rather
than by transactivation of EGF receptors as in some models
[15,16,33,34] so the observed ligand speciﬁcity and reversal by p38
Fig. 5. Inﬂuence of JNK and p38 inhibitors on modulation of ERK activation by DUSP knock-down. HeLa cells were transfected with control siRNA (ctrl.) or with siRNAs targeting
either DUSP 10 or DUSP 16 as indicated. They were then kept in mediumwith 0.1% FCS for 16 h and stimulated for 10 min with 10 nM EGF (upper panels) or with 1 μMPDBu (lower
panels), before being ﬁxed, stained and imaged as above. To determine inhibitor effects, cells were pre-treated for 30 min with 10 μM SB203580 p38 inhibitor (p38 inh., left panels),
with 10 μM SP600125 JNK inhibitor (JNK inh., right panels) or with medium alone (Ctrl, all panels) before addition of the stimulus. Average whole cell ppERK1/2 measures were
calculated and normalized to internal control values (ppERK1/2 levels in EGF- or PDBu-stimulated cells with control siRNA and no inhibitor). The data shown are means±SEMs
(n=3) pooled from 3 separate experiments each with triplicate wells. Two-way ANOVA of the data in A revealed that DUSP siRNA, p38 inhibitor and the siRNA/inhibitor interaction
were all signiﬁcant variables (Pb0.01) and post-hoc tests revealed that p38 inhibition increased ppERK1/2 levels in the presence of either siRNA (**, Pb0.01) but not in its absence.
ANOVA for the data in B revealed signiﬁcance only for the DUSP siRNA effect (Pb0.01) and the post-hoc tests showed no signiﬁcant effects of JNK inhibition. ANOVAs performed for
the PDBu-treated cells (C and D) revealed each of the inhibitors to be signiﬁcant variables (Pb0.01 for p38 inhibition and Pb0.05 for JNK inhibition) but the siRNA and interaction
terms were not signiﬁcant, nor was statistical signiﬁcance revealed by the post-hoc tests.
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distal to the EGF receptor but also upstream of Raf and b) is p38 me-
diated. We further explored this possibility by mathematical model-
ing, extending model A (above) to incorporate parallel activation of
two MAPK pathways (ERK and p38) and negative feedback of p38
at upstream points in the EGF receptor/ERK pathway (model
B=steps 1–6 in Supplemental Fig. 1). The model prediction is that
p38 targeted DUSPs will reduce p38 activity, thereby reducing the
negative feedback and enhancing the ERK response. Conversely, the
model predicts that knock-down of the p38 DUSP will increase the
negative feedback and thereby reduce the ERK response (Supplemen-
tal Fig. 5). Clearly mathematical modeling alone cannot prove or dis-
prove this signal architecture but it is consistent with experimental
data showing that EGF causes parallel activation of ERK and p38 in
some models [40–42], and that p38 activation can accelerate EGF re-
ceptor internalisation [42] providing a potential mechanism for the
upstream negative feedback. It is also entirely consistent with the
knock-down data and inhibitor experiments shown here (Figs. 3–5).
Our data also support a recent study showing that over-expression
of DUSP 16 converts a modest and transient EGF-stimulated ppERK1/
2 response to a more pronounced and sustained response in COS-7
cells [32], yet the mechanism proposed for the latter effect differsmarkedly from the one suggested here. In COS-7 cells, over-
expression of DUSP 16 enhanced ppERK1/2 responses to activation
with PDBu as well as EGF [32], acting by scaffolding and retaining
ppERK1/2 within the cytoplasm and thereby preventing ERK-
mediated transcriptional responses. Having used an automated cell
imaging readout for ERK1/2 activation we have accumulated mea-
sures of nuclear and cytoplasmic ERK1/2 and ppERK1/2 for many
thousands of individual cells and therefore used this data to explore
possible effects of DUSP knock-downs on ERK1/2 distribution in our
HeLa cell model (Supplemental Figs. 6 and 7). We ﬁrst used popula-
tion averaged responses and, as expected, these revealed pronounced
and comparable stimulatory effects of EGF and PDBu on whole cell
ppERK1/2 levels, as well as inhibition of the EGF effect (but not the
PDBu effect) by siRNAs targeting DUSP 10 or 16 (Fig. 6A, see also
Fig. 4). As with earlier work showing stimulus-induced translocation
of ERK from the cytoplasm to the nucleus, we found that EGF and
PDBu both increased the N:C ERK1/2 ratio and, as expected, the
PDBu effect was more pronounced than that of EGF (Fig. 6A, see
also Refs. [15,16,33,34]). DUSP 10 siRNA had no measurable effect
on N:C ERK1/2 under any condition, (arguing against a scaffolding
role) whereas knock-down of DUSP 16 caused a pronounced increase
in N:C ERK1/2 in control cells (Fig. 6A). This occurred without any
Fig. 6. Relationships between ERK phosphorylation and nuclear translocation. Panel A: HeLa cells were transfected with control siRNA or with siRNAs targeting either DUSP 10 or
DUSP 16, as indicated. They were then kept in medium with 0.1% FCS for 16 h prior to stimulation EGF (10 nM) PDBu (1 μM) or medium alone (ctrl.) for 10 min. They were then
ﬁxed, stained and imaged as above, except that the cells were stained for total ERK1/2 as well as ppERK1/2 and DAPI, and image analysis was used to calculate not only whole cell
ppERK1/2 levels, but also average nuclear and cytoplasmic ERK1/2 staining intensity, so that the nuclear:cytoplasmic ratio (N:C ERK1/2) could be calculated. The data shown are
means±SEMs. * Pb0.05 compared to control cells without stimulus or DUSP siRNA. † Pb0.05 compared to the stimulus matched control siRNA group (open bars). Panel B: cells
from the same experiment were binned (mathematically) according to whole cell ppERK1/2 levels, to generate sub-populations of control cells in which ppERK1/2 was 80–
120 AFU, and EGF- or PDBu-stimulated cells in which ppERK1/2 was 680–720 AFU. The N:C ERK1/2 ratio was then calculated for these binned cell sub-populations. The data
shown are means±SEMs. * Pb0.05 compared to control cells without stimulus or DUSP siRNA. † Pb0.05 compared to matched control siRNA group (open bars). Note that
knock-down of DUSP 10 or 16 has no measurable effect on ppERK1/2 levels (upper right) because the data are binned, yet EGF, PDBu and DUSP 16 siRNA all increased N:C
ERK1/2 in these ppERK1/2 matched populations.
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endogenous DUSP 16 does indeed scaffold and retain ERK1/2 in the
cytoplasm of unstimulated cells. However, the effects of DUSP 16
siRNA and stimulation (with EGF or PDBu) were not additive and
DUSP 16 siRNA failed to cause any measurable change in N:C ERK1/
2 in the presence of EGF or PDBu, arguing against a scaffolding func-
tion in the stimulated cells (Fig. 6A).
We further explored a possible scaffolding effect in sub-
populations of cells binned according to ppERK1/2 levels as described
[33]. We ﬁrst examined frequency–distribution plots for whole cell
ppERK1/2 and N:C ERK1/2 levels in control and PDBu-stimulated
cells treated with control siRNA or DUSP 16 siRNA (Supplemental
Fig. 7) in order to select narrow bins of ppERK1/2 levels representa-
tive of control and stimulated cells (80–120 and 680–720 AFU, re-
spectively). We then calculated N:C ERK1/2 values in these sub-
populations. Here, the idea is that comparison of test and control
cells with matched ppERK1/2 levels reveals effects on distribution
that are not due solely due to TEY phosphorylation of ERK. For exam-
ple, we have shown that sustained stimulation with PDBu causes a
pronounced increase in N:C ERK1/2 in sub-populations matched for
ppERK1/2, an effect that likely reﬂects the ability of PDBu to
increase expression of nuclear-inducible MKP scaffolds [33]. Taking
a similar approach to explore any possible scaffolding effect of
DUSPs 10 and 16, we found that ppERK1/2 levels in the binned cells
were (inevitably) higher in the stimulated cells than the controls
and importantly, were not measurably inﬂuenced by the siRNAs
(Fig. 6B upper panel). The N:C ERK1/2 values were higher in EGF- or
PDBu-stimulated cells than in the control cells (largely because of
the higher ppERK1/2 values) and the N:C ERK1/2 values were higher
in PDBu-stimulated cells than after EGF stimulation (Fig. 6B), consistent
with earlier work showing that PDBu causes a pronounced nuclear ac-
cumulation of ERK that is not entirely attributable to TEY phosphoryla-
tion of ERK1/2 [33]. siRNA targeting DUSP 16 caused a pronounced
increase in N:C ERK1/2 (under conditions in which it had no effect onwhole cell ppERK1/2), conﬁrming the scaffolding effect of endogenous
DUSP 16 in control cells. However, knock-down of DUSP 10 had no ef-
fect on N:C ERK2-GFP under any condition, and knock-down of DUSP
16 had no measurable effect on N:C ERK1/2 in the presence of EGF or
PDBu (Fig. 6B). Thus our data demonstrate a TEY phosphorylation unat-
tributable effect of DUSP 16 siRNA (that most likely reﬂects a cytoplas-
mic scaffolding effect of DUSP 16), but only in control cells. No such
effect was seen in the presence of EGF or PDBu, arguing against a scaf-
folding function in stimulated HeLa cells.
We also tested for possible effects of siRNAs targeting DUSPs 10
and 16 on ERK-mediated transcription using an Egr-1 luciferase
(luc) reporter. As shown (Fig. 7), stimulation for 2 h with EGF and
PDBu caused dose-dependent increases in Egr-1-luc activity (see
also Refs. [15,33,34]). Knock-down of either DUSP reduced the tran-
scriptional effects of EGF, as anticipated from the effect of these
knock-downs on ppERK1/2 (Fig. 4). Speciﬁcity is indicated by the
fact that no signiﬁcant inhibition was seen after knock-down of
DUSP 2 (not shown). Surprisingly, siRNAs targeting DUSPs 10 or 16
also inhibited Egr-1-luc responses to PDBu (Fig. 7) in spite of having
no effect on ppERK1/2 responses in cells stimulated 0–14 min
(Fig. 4). However, this discrepancy may simply reﬂect differences in
time courses, as we have previously shown that knock-down of
DUSP 10 or 16 does reduce PDBu effects on ppERK1/2 at 2–4 h [15].
We attempted to address this by varying the stimulation period in
the transcription assays but qualitatively similar data were obtained
with 1, 2 and 4 h stimulation (not shown) and shorter incubation pe-
riods were considered impractical. We speculate that knock-down of
these DUSPs would differentially modulate acute ERK-mediated ef-
fects (i.e. phosphorylation and regulation of pre-existing cytoplasmic
targets) but not chronic effects (i.e. those dependent upon protein
neosynthesis). Most importantly, however, DUSPs 10 and 16 knock-
down effects reveal these DUSPs as positive regulators of EGF and
ERK-driven transcription, as opposed to the negative regulatory role
of DUSP 16 seen in COS-7 cells [32]. The reason for this difference is
Fig. 7. Inﬂuence of DUSPs 10 and 16 knock-down on ERK-mediated transcription. HeLa cells were transfected with control siRNA or with siRNAs targeting either DUSP 10 or DUSP
16, and incubated with Ad Egr-1 Luciferase or Ad CMV β-galactosidase reporter vectors. After culture, they were stimulated for 2 h with the indicated concentrations of EGF (left
panel) or PDBu (right panel), washed, lysed and assessed for luciferase activity as described in Materials and methods. Luciferase activity was normalized to the internal control
maximal responses for EGF and PDBu respectively) and are pooled from 3 separate experiments, each with 3 replicates (mean±SEM, n=3). Two-way ANOVA and Bonferroni
post-test revealed signiﬁcant inhibition (Pb0.01) at all EGF concentrations with both DUSP 10 siRNA and DUSP 16 siRNA, although neither has a signiﬁcant effect in the control
cells without EGF. Similarly, DUSP 10 siRNA signiﬁcantly reduced responses to PDBu at 10−8 to 10−5 M (Pb0.05 or Pb0.01). DUSP 16 siRNA also signiﬁcantly reduced responses
















Fig. 8. Schematic representation of acute ERK regulation pathways. Model A indicates
the initial pathway with ppERK1/2 mediated negative feedback but without ppp38-
mediated cross-talk (equations 1–4 in Supplemental Fig. 1). Model B incorporates nega-
tive feedback from ppp38 (equations 1–6 in Supplemental Fig. 1)). Our data reveal no
role for direct DUSP-mediated inactivation of ppERK (by phosphatase (pASE) 1 in model
A) in shaping ERK responses. Instead, they suggest that acute EGF effects on ERK are sub-
ject to upstream ppp38-mediated negative feedback that is enhanced by knock-down of
DUSPs 10 and/or 16 (pASE 2 in model B). Thus, the major effect of DUSPs on acute EGF
effects in this model appears to be exerted by modulation of cross-talk rather than by di-
rect dephosphorylation of ppERK1/2.
1010 A.R. Finch et al. / Cellular Signalling 24 (2012) 1002–1011unknown although it could clearly relate to the use of different cell
types (HeLa versus COS-7) in which the signal network architecture
places different reliance on scaffolding versus p38-mediated cross-
talk to shape ERK signals. Another possibility is that a scaffolding
function of DUSP 16 in stimulated cells is negligible at physiological
expression levels and is therefore revealed by over-expression [32]
but not by knock-down (Fig. 6).
4. Conclusions
We have explored the possible role of DUSPs on acute EGF-
mediated ERK signalling using high content imaging and a delayed
MEK inhibition protocol to distinguish direct and indirect effects on
ERK activity. We were unable to ﬁnd evidence that any of the MKPs
expressed in HeLa cells act directly to dephosphorylate ppERK1/2 in
the acute time-frame tested. Instead, we ﬁnd that two p38/JNK
MKPs (DUSPs 10 and 16) are positive regulators of acute EGF-
stimulated ERK activation, apparently acting by modulating cross-
talk between the p38 and ERK pathways. In this model (shown as a
cartoon in Fig. 8 and mathematically as equations 1–6 in Supplemen-
tal Fig. 1) the major mechanism by which MKPs inﬂuence acute EGF-
stimulated ERK responses is the negative regulation of p38, resulting
in the positive regulation of ERK phosphorylation and activity.
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